文献速递冠心病

大尺寸自膨胀瓣膜TAVI术后短期与长期结局

Short‐ and Long‐Term Outcomes After Transcatheter Aortic Valve Implantation With Large Self‐Expanding Valves
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-09-21

该研究比较接受大尺寸(34 mm)Evolut瓣膜与常规尺寸(23-29 mm)Evolut瓣膜行TAVI治疗主动脉瓣狭窄患者的结局。倾向性评分匹配后两组各141例,30天死亡率、卒中及新发起搏器植入率无明显差异。5年随访显示两组在全因死亡率、卒中、心衰再住院及新发起搏器植入方面均无显著差异。

要点

  • 大尺寸(34 mm)自膨胀瓣膜TAVI术后5年结局与常规尺寸瓣膜相当。
  • 两组30天死亡率、卒中及新发起搏器植入率差异均无统计学意义。
  • 大尺寸瓣膜组结构性瓣膜退化、感染性心内膜炎及再次干预均少见。

核心结论

  • 大尺寸自膨胀瓣膜TAVI术后结局与常规尺寸瓣膜相当,5年随访结果良好。

研究设计与样本

  • 2015年1月至2025年11月共488例患者接受不同代际Evolut瓣膜TAVI治疗自体主动脉瓣狭窄。
  • 采用1:1倾向性评分匹配队列,匹配后获得141对大尺寸与常规尺寸瓣膜患者。

主要发现

  • 186例(38%)接受大尺寸瓣膜,302例(62%)接受常规尺寸瓣膜。
  • 匹配后两组年龄(80±6 vs. 81±6岁)、STS-PROM评分(3.2[2.0-4.9] vs. 3.6[2.1-5.8])及男性比例(96% vs. 97%)可比。
  • 操作技术成功率(95% vs. 94%)、器械成功率(90% vs. 92%)及早期安全性(79% vs. 79%)相当。
  • 30天死亡率(2.1% vs. 1.4%)、卒中(2.1% vs. 3.5%)及新发起搏器植入率(12% vs. 11%)差异均无统计学意义。
  • 5年全因死亡率HR 1.06(95% CI 0.64-1.76,p=0.8),卒中sHR 0.74(95% CI 0.26-2.11,p=0.6),心衰再住院sHR 0.96(95% CI 0.46-2.01,p=0.9),新发起搏器sHR 1.02(95% CI 0.57-1.82,p=0.9)。

临床怎么用

  • 对于大主动脉瓣环解剖的患者,使用34 mm自膨胀瓣膜行TAVI可获得与常规尺寸瓣膜相似的近远期结局。

局限性

  • 非随机设计,主要比较在倾向性评分匹配队列中进行以平衡基线差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Patients with large aortic annuli are a more challenging subgroup for transcatheter aortic valve implantation (TAVI), and data on long-term outcomes are sparse. Aims Compare outcomes of patients with large annular anatomies to outcomes of patients with regular anatomies. Methods Between January 2015 and November 2025, 488 patients underwent TAVI with different generations of Evolut valves for the treatment of native aortic stenosis. Outcomes of large 34 mm valves were compared to regular size 23−29 mm valves. To account for the nonrandomized design, the primary comparison was performed in a 1:1 propensity score matching cohort. Results A total of 186 (38%) patients received large and 302 (62%) received regular size valves. Propensity score matching yielded 141 well-balanced pairs, in whom age (80 ± 6 vs. 81 ± 6 years), STS-PROM score (3.2 [2.0−4.9] vs. 3.6 [2.1−5.8]), and male sex (96% vs. 97%), were comparable. Procedural technical success (95% vs. 94%), device success (90% vs. 92%), and early safety (79% vs. 79%) were comparable. At 30 days, mortality (2.1% vs. 1.4%), stroke (2.1% vs. 3.5%), and new pacemaker implantation (12% vs. 11%) did not differ significantly. At 5 years, there were no significant differences between the groups in all-cause mortality (HR 1.06, 95% CI 0.64–1.76, p = 0.8), stroke (sHR 0.74, 95% CI 0.26−2.11, p = 0.6), heart failure rehospitalization (sHR 0.96, 95% CI 0.46−2.01, p=0.9), or new pacemaker implantation (sHR 1.02, 95% CI 0.57−1.82, p = 0.9). Structural valve deterioration stage 3 (0% vs. 1.6%), infective endocarditis (1.7% vs. 2.8%), and valve reintervention (0% vs. 0.9%) were infrequent in both groups. The findings were consistent in the whole-cohort analysis. Conclusion Outcomes after TAVI with large self-expanding valves were comparable to regular size valves, demonstrating favorable results up to 5 years of follow-up.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Short‐ and Long‐Term Outcomes After Transcatheter Aortic Valve Implantation With Large Self‐Expanding Valves

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。